

510(k) Summary

| | |
|---------------------|--|
| Introduction | According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence. |
|---------------------|--|

| | |
|---|--|
| Submitter name, address, contact | <p>Roche Diagnostics Corporation 9115 Hague Road Indianapolis, IN 46250 (317) 576 - 3544</p> <p>Contact Person: Kay A. Taylor</p> <p>Date Prepared: March 28, 2000</p> |
|---|--|

| | |
|--------------------|---|
| Device Name | <p>Proprietary name: Elecsys® Anti-TPO CalCheck</p> <p>Common name: Calibration Verification Material</p> <p>Classification name: Single (specified) analyte controls (assayed + unassayed)</p> |
|--------------------|---|

| | |
|-----------------------------|--|
| Predicate device | The Elecsys® Anti-TPO CalCheck is substantially equivalent to the currently marketed Elecsys CalCheck TSH. |
|-----------------------------|--|

| | |
|-------------------------------|---|
| Device Description | The Elecsys® Anti-TPO CalCheck is a lyophilized product manufactured using a human serum base and human anti-TPO antibodies. The analyte is appropriately spiked into the CalCheck matrix to the correct CalCheck concentration levels. |
|-------------------------------|---|

510(k) Summary, Continued

| | |
|---------------------------------------|--|
| Intended use | The Elecsys® Anti-TPO CalCheck is used to verify the calibration of the Elecsys® Anti-TPO assay. |
| Comparison to predicate device | <p>The Elecsys® Anti-TPO CalCheck is substantially equivalent to other products in commercial distribution intended for similar use. Most notably, it is substantially equivalent to the currently marketed Elecsys® CalCheck™ TSH.</p> <p>Both products are intended to be used for the verification of calibration for analytes on the Elecsys® Immunoassay Analyzers.</p> |
| Performance Characteristics | The Elecsys® Anti-TPO CalCheck was evaluated for value assignment and stability. |



DEPARTMENT OF HEALTH & HUMAN SERVICES

JUN - 1 2000

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Ms. Kay A. Taylor
Regulatory Affairs, Laboratory Systems
Roche Diagnostics Corporation
9115 Hague Road
P.O. Box 50457
Indianapolis, Indiana 46250-0457

Re: K001014
Trade Name: Elecsys Anti-TPO CalCheck
Regulatory Class: I
Product Code: JJX
Dated: March 28, 2000
Received: March 29, 2000

Dear Ms. Taylor:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895.


A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical Laboratory Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

Indications for Use Statement

510(k) Number (if known): N/A K001014

Device Name: Elecsys® Anti-TPO CalCheck

Indications For Use:

Elecsys® Anti-TPO CalCheck calibration verification solutions comprise three levels - low, mid, and high - each with a defined Anti-TPO concentration. The low solution concentration is near the lower detection limit of the assay. The middle solution is in the middle or at the clinically critical point of the measuring range. The high solution is near the upper limit of the measuring range.


The Elecsys® Anti-TPO CalCheck is intended for use in periodic verification of the calibration of the Elecsys® Anti-TPO assay.

Prescription Use ✓
(Per 21 CFR 801.109)

OR

Over-The-Counter Use _____

(Optional Format 1-2-96)


(Division Sign-Off)

Division of Clinical Laboratory Devices

510(k) Number _____

K001014